<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220596</url>
  </required_header>
  <id_info>
    <org_study_id>ML25206</org_study_id>
    <nct_id>NCT01220596</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.</brief_title>
  <acronym>POTENT</acronym>
  <official_title>A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepatitis B.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hanyang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of Peginterferon alfa-2a following Entecavir compared with
      Peginterferon alfa-2a monotherapy in patient with HBeAg positive chronic hepatitis B.

        -  Increased HBeAg seroconversion rate

        -  Increased HBsAg loss rate

        -  To define the best treatment condition for chronic HBV hepatitis patients
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBeAg seroconversion</measure>
    <time_frame>24 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of HBsAg titer</measure>
    <time_frame>24 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of combined HBeAg seroconversion and HBV DNA &lt; 300 copies/ml</measure>
    <time_frame>24 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of serum HBV DNA &lt; 300 copies</measure>
    <time_frame>24 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of ALT normalization</measure>
    <time_frame>24 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of HBsAg loss</measure>
    <time_frame>24 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon alfa-2a monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir and Pegylated interferon α-2a Sequential Treatment Group</intervention_name>
    <description>Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks</description>
    <arm_group_label>Sequential therapy</arm_group_label>
    <other_name>Generic/Brand name: Pegylated interferon α-2a/Pegasys(TM)</other_name>
    <other_name>Generic/Brand name: Entecavir/Baraclude(TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon α-2a Monotreatment Group</intervention_name>
    <description>Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks</description>
    <arm_group_label>Peginterferon alfa-2a monotherapy</arm_group_label>
    <other_name>Generic/Brand name: Pegylated interferon α-2a/Pegasys(TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B patients with HBeAg positive, HBsAg positive, HBV DNA &gt; 100,000
             copies/ml and anti-HBs negative, serum ALT exceeding 2 X ULN but less than 10 X ULN.

        Exclusion Criteria:

          -  Patient infected concurrently with HCV, HDV and HIV or patient with a history of
             antiviral treatment for Hepatitis B or patient with hepatic decompensation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Hyun Sohn, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo Hyun Sohn, MD, Ph.D</last_name>
    <phone>+82-31-560-2225</phone>
    <email>sonjh@hanyang.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dae-Won Jun, MD, Ph.D</last_name>
    <phone>+82-2-2290-8338</phone>
    <email>noshin@hanyang.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <state>Chungcheongnam-do</state>
        <zip>330-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Il-Han Song, MD, Ph.D</last_name>
      <phone>+82-41-550-6694</phone>
      <email>ihsong21@dankook.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Il-Han Song, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon-do</state>
        <zip>200-704</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Joon Kim, MD, Ph.D</last_name>
      <phone>+82-33-240-5646</phone>
      <email>djkim@hallym.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong-Joon Kim, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soon Koo Baik, MD, Ph.D</last_name>
      <phone>+82-33-741-0114</phone>
      <email>paiksk@yonsei.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Soon Koo Baik, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-gyune Kim, MD, MS</last_name>
      <phone>+82-32-621-5114</phone>
      <email>mcnulty@schbc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang-Gyune Kim, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri</city>
        <state>Gyeonggi-do</state>
        <zip>471-854</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Hyun Sohn, MD, Ph.D</last_name>
      <phone>+82-31-560-2225</phone>
      <email>sonjh@hanyang.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Joo Hyun Sohn, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bundang CHA medical center</name>
      <address>
        <city>Sungnam</city>
        <state>Gyeonggi-do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Gyu Hwang, MD, Ph.D</last_name>
      <phone>+82-31-780-5000</phone>
      <email>sghwang@cha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seong-Gyu Hwang, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Busan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnam-do</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki-Tae Yoon, MD, MS</last_name>
      <phone>82-55-360-1412</phone>
      <email>ktyoon@pnuyh.co.kr</email>
    </contact>
    <investigator>
      <last_name>Ki-Tae Yoon, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <state>Jeju-do</state>
        <zip>690-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Cheol Song, MD, Ph.D</last_name>
      <phone>+82-64-717-1114</phone>
      <email>drsong@cheju.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Byung-Cheol Song, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A University Medical Center</name>
      <address>
        <city>Busan</city>
        <zip>602-103</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sungwook Lee, MD, Ph.D</last_name>
      <phone>+82-51-240-2400</phone>
      <email>sunglee@dau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sungwook Lee, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-cheol Yun, MD, Ph.D</last_name>
      <phone>+82-51-990-6114</phone>
      <email>ybchepa@ns.kosinmed.or.kr</email>
    </contact>
    <investigator>
      <last_name>Byung-Cheol Yun, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>612-030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-ha Park, MD, Ph.D</last_name>
      <phone>+82-51-797-0100</phone>
      <email>obgyy@medimail.co.kr</email>
    </contact>
    <investigator>
      <last_name>Seung-Ha Park, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-young Tak, MD, Ph.D</last_name>
      <phone>+82-53-420-5114</phone>
      <email>wytak@knu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Won-Young Tak, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heon-Ju Lee, MD, Ph.D</last_name>
      <phone>+82-53-623-8001</phone>
      <email>hjlee@ymu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Heon-Ju Lee, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Ik Kim, MD, Ph.D</last_name>
      <phone>82-2-2001-2050</phone>
      <email>bik.kim@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Byung-Ik Kim, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyunghee university Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Ho Kim, MD, Ph.D</last_name>
      <phone>+82-2-958-8114</phone>
      <email>kimbh@khu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Byung-Ho Kim, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>133-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae-Won Jun, MD, Ph.D</last_name>
      <phone>+82-2-2290-8338</phone>
      <email>noshin@hanyang.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dae-Won Jun, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung-Su Kim, MD, MS</last_name>
      <phone>+82-2224-2562</phone>
      <email>hskim@hallym.or.kr</email>
    </contact>
    <investigator>
      <last_name>Hyoung-Su Kim, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ja-Kyung Kim, MD, Ph.D</last_name>
      <phone>+82-2-2019-2330</phone>
      <email>ceciliak@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Ja-Kyung Kim, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-Choong Choi, MD, Ph.D</last_name>
      <phone>+82-2-950-1001</phone>
      <email>wcc829@paik.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Won-Choong Choi, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>so young Kwon, MD, Ph.D</last_name>
      <phone>+82-2-2030-7070</phone>
      <email>sykwonmd@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>So-Young Kwon, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2010</study_first_posted>
  <last_update_submitted>July 1, 2011</last_update_submitted>
  <last_update_submitted_qc>July 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Joo Hyun Sohn / Professor</name_title>
    <organization>Hanyang University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

